Glaucoma - Pipeline Review, H2 2020

September 2020 | 385 pages | ID: G6ABB164C82EN
Global Markets Direct

Abstracts

Glaucoma - Pipeline Review, H2 2020

SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Glaucoma - Pipeline Review, H2 2020, provides an overview of the Glaucoma (Ophthalmology) pipeline landscape.
Glaucoma is a disease of the eye in which fluid pressure within the eye rises. The exact cause of optic nerve damage from glaucoma is not fully understood, but involves mechanical compression and/or decreased blood flow of the optic nerve. The most important risk factors include age, elevated eye pressure, African ancestry, thin cornea, family history of glaucoma. Signs and symptoms include eye pain, nausea and vomiting (accompanying the severe eye pain), sudden onset of visual disturbance, often in low light, blurred vision and reddening of the eye.

REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Glaucoma - Pipeline Review, H2 2020, provides comprehensive information on the therapeutics under development for Glaucoma (Ophthalmology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Glaucoma (Ophthalmology) pipeline guide also reviews of key players involved in therapeutic development for Glaucoma and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 3, 14, 18, 12, 4, 70, 19 and 5 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 13 and 3 molecules, respectively.
Glaucoma (Ophthalmology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note:
Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

• The pipeline guide provides a snapshot of the global therapeutic landscape of Glaucoma (Ophthalmology).
• The pipeline guide reviews pipeline therapeutics for Glaucoma (Ophthalmology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
• The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
• The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
• The pipeline guide reviews key companies involved in Glaucoma (Ophthalmology) therapeutics and enlists all their major and minor projects.
• The pipeline guide evaluates Glaucoma (Ophthalmology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
• The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
• The pipeline guide reviews latest news related to pipeline therapeutics for Glaucoma (Ophthalmology)

REASONS TO BUY

• Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
• Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
• Find and recognize significant and varied types of therapeutics under development for Glaucoma (Ophthalmology).
• Classify potential new clients or partners in the target demographic.
• Develop tactical initiatives by understanding the focus areas of leading companies.
• Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
• Formulate corrective measures for pipeline projects by understanding Glaucoma (Ophthalmology) pipeline depth and focus of Indication therapeutics.
• Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
• Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Contents

Introduction
Glaucoma - Overview
Glaucoma - Therapeutics Development
Glaucoma - Therapeutics Assessment
Glaucoma - Companies Involved in Therapeutics Development
Glaucoma - Drug Profiles
Glaucoma - Dormant Projects
Glaucoma - Discontinued Products
Glaucoma - Product Development Milestones
Appendix

List Of Tables

LIST OF TABLES

Number of Products under Development for Glaucoma, H2 2020
Number of Products under Development by Companies, H2 2020
Number of Products under Development by Universities/Institutes, H2 2020
Products under Development by Companies, H2 2020
Products under Development by Universities/Institutes, H2 2020
Number of Products by Stage and Target, H2 2020
Number of Products by Stage and Mechanism of Action, H2 2020
Number of Products by Stage and Route of Administration, H2 2020
Number of Products by Stage and Molecule Type, H2 2020
Glaucoma - Pipeline by AbbVie Inc, H2 2020
Glaucoma - Pipeline by AC Immune SA, H2 2020
Glaucoma - Pipeline by Aerie Pharmaceuticals Inc, H2 2020
Glaucoma - Pipeline by Aerpio Pharmaceuticals Inc, H2 2020
Glaucoma - Pipeline by Allergan Ltd, H2 2020
Glaucoma - Pipeline by Amgen Inc, H2 2020
Glaucoma - Pipeline by Annexon Inc, H2 2020
Glaucoma - Pipeline by Annovis Bio Inc, H2 2020
Glaucoma - Pipeline by Asha Vision LLC, H2 2020
Glaucoma - Pipeline by Betaliq Inc, H2 2020
Glaucoma - Pipeline by Better Life Pharmaceuticals Inc, H2 2020
Glaucoma - Pipeline by Bial - Portela & Ca SA, H2 2020
Glaucoma - Pipeline by BioAxone BioSciences Inc, H2 2020
Glaucoma - Dormant Projects, H2 2020
Glaucoma - Discontinued Products, H2 2020

List Of Figures

LIST OF FIGURES

Number of Products under Development for Glaucoma, H2 2020
Number of Products under Development by Companies, H2 2020
Number of Products under Development by Universities/Institutes, H2 2020
Number of Products by Top 10 Targets, H2 2020
Number of Products by Stage and Top 10 Targets, H2 2020
Number of Products by Top 10 Mechanism of Actions, H2 2020
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2020
Number of Products by Top 10 Routes of Administration, H2 2020
Number of Products by Stage and Top 10 Routes of Administration, H2 2020
Number of Products by Top 10 Molecule Types, H2 2020
Number of Products by Stage and Top 10 Molecule Types, H2 2020

COMPANIES MENTIONED

AbbVie Inc
AC Immune SA
Aerie Pharmaceuticals Inc
Aerpio Pharmaceuticals Inc
Allergan Ltd
Amgen Inc
Annexon Inc
Annovis Bio Inc
Asha Vision LLC
Betaliq Inc
Better Life Pharmaceuticals Inc
Bial - Portela & Ca SA
BioAxone BioSciences Inc
Biozeus Pharmaceutical SA
Califia Bio Inc
Calpain Therapeutics Pty Ltd
Cellix Bio Pvt Ltd
Certa Therapeutics Pty Ltd
Chong Kun Dang Pharmaceutical Corp
D. Western Therapeutics Institute Inc
Deha Pharmaceutical LLC
Dhp Korea Ltd
Disarm Therapeutics Inc
Dompe Farmaceutici SpA
Emerald Bioscience Inc
Emerald Organic Products Inc
Envisia Therapeutics Inc
Evotec SE
EyePoint Pharmaceuticals Inc
Eyevensys SAS
Fortress Biotech Inc
Future Medicine Co Ltd
Galimedix Therapeutics Ltd
Gene Signal International SA
Glaukos Corp
Graybug Vision Inc
Guangzhou Cellprotek Pharmaceutical Co Ltd
Guangzhou Magpie Pharmaceutical Co Ltd
Gurus BioPharm
Handok Inc
HitGen Inc
HK inno.N Corp
ID Pharma Co Ltd
Il Dong Pharmaceutical Co Ltd
InMed Pharmaceuticals Inc
Inspyr Therapeutics Inc
Isarna Therapeutics GmbH
Kedalion Therapeutics Inc
Kodiak Sciences Inc
Kowa Co Ltd
Kukje Pharmaceutical Industry Co Ltd
Kyoto Drug Discovery & Development Co Ltd
Laboratoires Thea SA
Laboratorios Salvat SA
Laboratorios Sophia SA de CV
LayerBio Inc
Lee's Pharmaceutical Holdings Ltd
Luminus Biosciences Inc
Matrix Biomed Inc
MimeTech Srl
MyX Therapeutics Inc
Nanoscope Therapeutics Inc
NeurAegis Inc
Neurim Pharmaceuticals Ltd
Neurizon Pharma GBR
Neuroptika Inc
NeuroScientific Biopharmaceuticals Ltd
NicOx SA
NoNO Inc
Novaliq GmbH
Novartis AG
Noveome Biotherapeutics Inc
Novoron Bioscience Inc
OccuRx Pty Ltd
Ocular Therapeutix Inc
Oculo Therapy LLC
Ocuphire Pharma Inc
Oncolys BioPharma Inc
ONL Therapeutics Inc
Palo BioFarma SL
pH Pharma Co Ltd
Pinotbio Inc
Profarma
Q BioMed Inc
Qlaris Bio Inc
Quark Pharmaceuticals Inc
Qurgen Inc
Radikal Therapeutics Inc
ReNetX Bio
Reven Pharmaceuticals Inc
Ripple therapeutics Corp
Santen Pharmaceutical Co Ltd
Stuart Therapeutics Inc
Sun Pharma Advanced Research Company Ltd
Sustained Nano Systems LLC
Sylentis SAU
TaeJoon Pharmaceuticals Co Ltd
TearClear Corp
Teraclon IDF SL
TikoMed AB
Toa Eiyo Ltd
Topadur Pharma AG
ViSci Ltd
Whitecap Biosciences LLC